Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Alvelestat
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MPH-966
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Details:
The Phase 1b/2 trial is a randomized, double-blind, placebo-controlled study to assess the safety and efficacy of alvelestat in adult patients hospitalized with moderate to severe COVID-19 respiratory disease not yet receiving mechanical ventilation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MultiStem Cell Therapy
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2020
Details:
Data from the completed Phase 1/2 acute respiratory distress Syndrome study, performed by Athersys, was presented at the International Society of Cell and Gene Therapy Virtual Conference.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ATYR1923
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2020
Details:
Company will present new data from preclinical AVR-RD-03 program for Pompe disease a and data updates for its investigational programs for Fabry disease and cystinosis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Organicell Flow
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2020
Details:
This trial will be the first randomized, double-blinded, placebo-controlled, phase I/II multi-center trial investigating the safety and efficacy of amniotic fluid sourced components for COVID-19.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
